Illumina, Inc. (NASDAQ:ILMN) Shares Sold by Cerity Partners LLC

Cerity Partners LLC trimmed its holdings in Illumina, Inc. (NASDAQ:ILMN) by 11.0% in the 4th quarter, HoldingsChannel reports. The fund owned 4,957 shares of the life sciences company’s stock after selling 612 shares during the quarter. Cerity Partners LLC’s holdings in Illumina were worth $691,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in ILMN. Vanguard Group Inc. grew its holdings in shares of Illumina by 15.0% during the 3rd quarter. Vanguard Group Inc. now owns 17,967,758 shares of the life sciences company’s stock worth $2,466,614,000 after purchasing an additional 2,336,935 shares during the period. Polen Capital Management LLC boosted its stake in Illumina by 0.6% during the third quarter. Polen Capital Management LLC now owns 5,126,614 shares of the life sciences company’s stock worth $703,782,000 after buying an additional 29,153 shares during the period. Loomis Sayles & Co. L P increased its position in shares of Illumina by 5.5% during the third quarter. Loomis Sayles & Co. L P now owns 4,007,957 shares of the life sciences company’s stock valued at $550,212,000 after acquiring an additional 208,267 shares during the last quarter. Bank of New York Mellon Corp raised its stake in shares of Illumina by 6.6% in the 3rd quarter. Bank of New York Mellon Corp now owns 3,648,935 shares of the life sciences company’s stock valued at $500,926,000 after acquiring an additional 225,074 shares during the period. Finally, Barclays PLC lifted its holdings in shares of Illumina by 120.0% in the 3rd quarter. Barclays PLC now owns 1,768,355 shares of the life sciences company’s stock worth $242,758,000 after acquiring an additional 964,709 shares during the last quarter. Institutional investors and hedge funds own 89.42% of the company’s stock.

Illumina Stock Performance

Shares of ILMN stock opened at $124.46 on Wednesday. The company has a market cap of $19.82 billion, a P/E ratio of -16.96 and a beta of 1.19. The firm has a fifty day moving average price of $132.79 and a 200 day moving average price of $127.58. The company has a current ratio of 1.66, a quick ratio of 1.29 and a debt-to-equity ratio of 0.26. Illumina, Inc. has a 12 month low of $89.00 and a 12 month high of $229.58.

Illumina (NASDAQ:ILMN) last issued its earnings results on Thursday, February 8th. The life sciences company reported $0.14 earnings per share for the quarter, topping the consensus estimate of $0.01 by $0.13. The business had revenue of $1.12 billion for the quarter, compared to analyst estimates of $1.09 billion. Illumina had a positive return on equity of 2.20% and a negative net margin of 25.78%. The business’s quarterly revenue was up 3.6% on a year-over-year basis. During the same quarter last year, the company earned $0.14 EPS. Sell-side analysts predict that Illumina, Inc. will post 0.91 earnings per share for the current fiscal year.

Insider Transactions at Illumina

In related news, CEO Jacob Thaysen bought 7,330 shares of the company’s stock in a transaction that occurred on Thursday, February 22nd. The shares were purchased at an average cost of $135.29 per share, with a total value of $991,675.70. Following the transaction, the chief executive officer now directly owns 14,861 shares of the company’s stock, valued at approximately $2,010,544.69. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders own 0.17% of the company’s stock.

Analysts Set New Price Targets

Several analysts recently weighed in on ILMN shares. Royal Bank of Canada reiterated an “outperform” rating and issued a $253.00 target price on shares of Illumina in a report on Tuesday, April 9th. StockNews.com raised Illumina from a “hold” rating to a “buy” rating in a research note on Friday, February 16th. OTR Global reissued a “mixed” rating on shares of Illumina in a research note on Wednesday, March 20th. TD Cowen cut Illumina from an “outperform” rating to a “market perform” rating and set a $144.00 target price for the company. in a report on Thursday, January 4th. Finally, HSBC lowered shares of Illumina from a “buy” rating to a “hold” rating in a research note on Tuesday, January 16th. Two equities research analysts have rated the stock with a sell rating, nine have given a hold rating and nine have issued a buy rating to the company’s stock. According to MarketBeat, Illumina has an average rating of “Hold” and a consensus target price of $167.70.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.